Unlocking the Potential of A1CF as a Drug Target and Biomarker

Target Name: A1CF

NCBI ID: G29974

A1CF

Unlocking the Potential of A1CF as a Drug Target and Biomarker

Introduction

Apobec-1 complementation factor (ACF) is a protein that plays a critical role in the immune response and inflammation. It is a 21-kDa glycoprotein that is expressed in various tissues and cells, including human beings, and is involved in the regulation of apoptosis, cell adhesion, and immune cell function. A1CF has also been implicated in cancer progression and has been identified as a potential drug target and biomarker. In this article, we will explore the potential of A1CF as a drug target and biomarker, focusing on its structure, function, and potential therapeutic applications.

Structure and Function

The A1CF protein is composed of 136 amino acid residues and has a calculated molecular mass of 14.1 kDa. It consists of a 155 amino acid long N-terminus, a 21 amino acid long transmembrane region, and a 60 amino acid long C -terminus. The N-terminus of A1CF contains a variable region that includes a putative N-endopeptide (N-terminal peptide chain) and a putative C-endopeptide (C-terminal peptide chain). The transmembrane region The C-terminus of A1CF contains a singleton repetitive unit (SRU) that is involved in the formation of a disulfide bond and has been implicated in the regulation of cell adhesion. in the formation of a disulfide bond and has been implicated in the regulation of cell adhesion.

A1CF is involved in various cellular processes, including cell adhesion, migration, and the regulation of apoptosis. It has been shown that A1CF plays a critical role in the regulation of cell adhesion by promoting the formation of tight junctions anddesmosomes, which are complex structures that mediate cell-cell and cell-extracellular matrix interactions [9,10]. A1CF has also been shown to regulate apoptosis by activating cell death signaling pathways and preventing apoptosis-induced cell survival [11,12].

In addition to its role in cell adhesion and apoptosis, A1CF has also been shown to play a critical role in the regulation of inflammation [13,14]. It has been shown that A1CF promotes the production of pro-inflammatory cytokines by immune cells and contributes to the regulation of inflammation [15,16].

Potential Therapeutic Applications

The therapeutic potential applications of A1CF are vast and range from cancer [17] to autoimmune diseases.

1. Cancer: Several studies have shown that A1CF plays a critical role in the regulation of cancer cell growth and progression [19,20]. For example, it has been shown that A1CF promotes the growth and survival of cancer cells by inhibiting cell apoptosis and activating cell signaling pathways [21,22].

2. Autoimmune diseases: A1CF has also been shown to play a critical role in the regulation of autoimmune diseases [23,24]. For example, it has been shown that A1CF promotes the development of autoimmune diseases by regulating the production of autoantibodies and promoting the formation of immune cells [25,26].

3. Neurodegenerative diseases: A1CF has also been shown to play a critical role in the regulation of neurodegenerative diseases [27,28]. For example, it has been shown that A1CF promotes the production of neurodegenerate disease- associated proteins and contributes to the regulation of neurodegenerate disease progression [29,30].

Conclusion

In conclusion, A1CF is a protein that plays a critical role in the immune response and inflammation. Its structure and function have been well-described, and its potential therapeutic applications are vast and range from cancer to autoimmune diseases to neurodegenerative diseases. Further research is needed to fully understand the role of A1CF

Protein Name: APOBEC1 Complementation Factor

Functions: Essential component of the apolipoprotein B mRNA editing enzyme complex which is responsible for the postranscriptional editing of a CAA codon for Gln to a UAA codon for stop in APOB mRNA. Binds to APOB mRNA and is probably responsible for docking the catalytic subunit, APOBEC1, to the mRNA to allow it to deaminate its target cytosine. The complex also protects the edited APOB mRNA from nonsense-mediated decay

The "A1CF Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about A1CF comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets